Article

CURE Inaugural Commercial to Air During SU2C Telecast

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight, announced Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of CURE Media Group. The commercial aims to give individuals with cancer a platform to voice how they are more than just patients.

“We are so honored to be recognized during the Stand Up To Cancer (SU2C) telecast,” said Michael J. Hennessy Jr., in making the announcement. “This is a huge achievement for the CURE Media Group and we are so thankful to get our message across airing our first commercial.”

CURE® message, “Today, I’m more than a patient,” will fill millions of screens during SU2C’s sixth biennial televised fundraising special. CURE® hopes viewers will share how they are more than a patient, using the hashtag #MoreThanAPatient on social media.

The commercial will air on CBS in New York, San Francisco and Boston on Friday, Sept. 7 at 8 p.m. ET/PT and 7 p.m. CT.

To see the commercial after it airs, visit http://www.curetoday.com or find us on Twitter @cure_magazine, Facebook @curemagazine or Instagram @curetoday.

Related Videos
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
1 expert is featured in this series.
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
1 expert is featured in this series.
Related Content